Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Tango Therapeutics, Inc.
Essen Biotech
Royal Marsden NHS Foundation Trust
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
University of Southern California
Memorial Sloan Kettering Cancer Center
Institut Bergonié
Maria Sklodowska-Curie National Research Institute of Oncology
Gustave Roussy, Cancer Campus, Grand Paris
Transgene
Seattle Children's Hospital
Memorial Sloan Kettering Cancer Center
ImmVira Pharma Co. Ltd
University of California, Irvine
Valo Therapeutics Oy
Epkin
Dana-Farber Cancer Institute
Yonsei University
University of Iowa
OncoC4, Inc.
Memorial Sloan Kettering Cancer Center